Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company, today reported the Robust Immune Response Phase IIb Data after which the GLSI stock price surged by
Sonoma Pharmaceuticals Inc. (SNOA) stock plunged -7.53% to $8.1 in the pre-market trading after reporting partnership with Crown Laboratories to launch Microcyn® technology-based anti-itch over-the-counter
Immutep Limited (NASDAQ: IMMP) shares are trading down -26.19% at $4.2 at the time of writing after reporting that its Chinese partner, EOC Pharma will
Xenetic Biosciences Inc. (XBIO) stock plunged -15.46% to $2.68 in the pre-market trading following the company’s announcement of $6.0 million registered direct offering priced at-the-market
It is evident with so many people focused on COVID-19 that biotech stocks with coronavirus vaccines and treatments have gained a lot of attention. The
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) stock jumped vigorously in the post-market trading hours, as the shares jumped 31.75% to reach $75.23 following, a clinical-stage biotech
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.